# Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

> **NCT00290277** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 300 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** HPV-16/18 L1/AS04

## Key facts

- **NCT ID:** NCT00290277
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290277, "Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00290277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*